TargetMol

Dexelvucitabine

Product Code:
 
TAR-T27154
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T27154-1mg1mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27154-5mg5mg£269.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27154-1mL1 mL * 10 mM (in DMSO)£289.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27154-10mg10mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27154-25mg25mg£603.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T27154-50mg50mg£830.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Dexelvucitabine, a nucleoside reverse transcriptase inhibitor, is used potentially for the treatment of HIV infection.
CAS:
134379-77-4
Formula:
C9H10FN3O3
Molecular Weight:
227.195
Pathway:
Microbiology/Virology
Purity:
0.9825
SMILES:
Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](CO)C=C1
Target:
Reverse Transcriptase

References

1. Meusinger R. Doubling spectroscopy challenge. Anal Bioanal Chem. 2015 Nov;407(27):8169-72. 2. Schinazi RF, et al. Selection and characterization of HIV-1 with a novel S68 deletion in reverse transcriptase. Antimicrob Agents Chemother. 2011 May;55(5):2054-60. 3. Elvucitabine data released at CROI. AIDS Patient Care STDS. 2010 Mar;24(3):198. 4. Colucci P, et al. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrob Agents Chemother. 2009 Feb;53(2):646-50.